Stable demand for resin-related products and pharmaceuticals
First written in FY2018-Q1. 11 of 25 entries say "Restated". Latest entry: 2026-08-06.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The specialty chemicals business posted a decrease in revenue in release agents and pharmaceutical applications due to the impact of inventory adjustments at customers. Going forward, in the phosgene derivatives business, we will further strengthen the business and work to expand its operating base and enhance competitiveness by maintaining and deepening our domestic production capabilities and establishing a global supply network through the acquisition of a base in Europe announced in March 2026.」
While the decrease in revenue due to inventory adjustments for release agents and pharmaceutical applications continued, the company indicated a policy of strengthening its supply network by combining domestic production capabilities with a European base. - FY2026-H1WorsenedAnnual report
「The specialty chemicals business posted a substantial decrease in revenue because demand for release agents and pharmaceutical applications declined, particularly overseas.」
Release agents and pharmaceutical applications, for which demand recovery had been indicated through the previous fiscal year, deteriorated into a substantial decrease in revenue due to declining demand. - FY2025-H1MitigatedAnnual report
「In the specialty chemicals business, demand for release agents and pharmaceutical applications recovered, particularly overseas, bringing results in line with the same period of the previous year.」
Although demand for pharmaceutical applications and release agents had remained weak through the previous fiscal year, it recovered, particularly overseas, bringing the business in line with the same period of the previous year. - FY2024-Q3RestatedAnnual report
「Meanwhile, demand in the specialty chemicals business for pharmaceutical applications and release agents remained depressed. The resin materials business also posted a substantial decrease in revenue, affected by inventory adjustments and other factors for polyurethane materials, mainly for overseas markets.」
Continued weak demand for pharmaceutical applications and release agents, together with inventory adjustments for polyurethane materials, was cited again as a factor behind the decrease in revenue from the functional resins segment. - FY2024-Q2RestatedAnnual report
「Meanwhile, demand in the specialty chemicals business for pharmaceutical applications and release agents remained sluggish. The resin materials business also posted a substantial decrease in revenue, affected by inventory adjustments for polyurethane materials, mainly for overseas markets.」
As in the previous quarter, sluggishness in pharmaceutical applications and release agents was cited as a factor behind the deterioration in the specialty chemicals business. - FY2024-Q1WorsenedAnnual report
「Meanwhile, the specialty chemicals business performed poorly in pharmaceutical applications, release agents and other products. The resin materials business also posted a substantial decrease in revenue, affected by inventory adjustments for polyurethane materials, mainly for overseas markets.」
Although pharmaceutical applications, release agents and other products had performed well through the previous fiscal year, both applications were sluggish this time and became factors behind the deterioration in the specialty chemicals business. - FY2022RestatedAnnual report
「The specialty chemicals business posted a substantial increase in revenue, as pharmaceutical applications, release agents and other products performed well.」
The strong performance of pharmaceutical applications, release agents and other products was also reflected in the full-year results through a substantial increase in revenue. - FY2022-Q3RestatedAnnual report
「In addition, the specialty chemicals business posted a substantial increase in revenue, as pharmaceutical applications, release agents and other products performed well.」
The substantial increase in revenue driven by strong performance in pharmaceutical applications, release agents and other products is continuing. - FY2022-Q2RestatedAnnual report
「In addition, the specialty chemicals business posted a substantial increase in revenue, as pharmaceutical applications, release agents and other products performed well.」
The substantial increase in revenue from the specialty chemicals business driven by strong performance in pharmaceutical applications, release agents and other products is continuing. - FY2022-Q1AdvancedAnnual report
「In addition, although pharmaceutical applications declined due to intensifying competition, the specialty chemicals business posted a substantial increase in revenue because demand for release agents and other products remained strong.」
While the decline in pharmaceutical applications due to intensifying competition continued, strong demand for release agents and other products drove a substantial increase in revenue for the business as a whole. - FY2021-Q3ReframedAnnual report
「In addition, the specialty chemicals business posted a substantial decrease in revenue due to intensifying competition for pharmaceutical intermediates and other factors.」
The explanation for the substantial decrease in revenue from pharmaceutical intermediates became more specific, changing from the previous explanation of declining demand to one citing intensifying competition and other factors. - FY2021-Q1WorsenedAnnual report
「In addition, although the release-agent business remained firm, demand for pharmaceutical intermediates declined, resulting in a substantial decrease in revenue in the specialty chemicals business.」
The business changed from an increase in revenue from winning large pharmaceutical intermediate projects in the previous full fiscal year to a substantial decrease in revenue due to declining demand for pharmaceutical intermediates. - FY2020ReframedAnnual report
「The specialty chemicals business posted a substantial increase in revenue, as pharmaceutical intermediates benefited from winning large projects and other factors. Although demand remains firm, price competition is intensifying, and we will continue working to secure both market share and profitability.」
In addition to the increase in revenue from winning large pharmaceutical intermediate projects, the company indicated that it must address intensifying price competition while securing both market share and profitability. - FY2020-Q3RestatedAnnual report
「The specialty chemicals business posted a substantial increase in revenue, as demand for pharmaceutical applications and other uses increased.」
The substantial increase in revenue driven by increased demand for pharmaceutical applications and other uses is continuing. - FY2020-Q2RestatedAnnual report
「Meanwhile, the Specialty Chemicals business posted a substantial increase in revenue as demand for pharmaceutical and other applications increased.」
A substantial increase in revenue from the specialty chemicals business, driven by increased demand for pharmaceutical applications and other uses, is continuing. - FY2020-Q1AdvancedAnnual report
「Meanwhile, the Specialty Chemicals business posted a substantial increase in revenue as demand for pharmaceutical and other applications increased.」
Although lower revenue due to intensifying competition in pharmaceutical applications had been reported for the full previous fiscal year, the current quarter posted a substantial increase in revenue due to increased demand for pharmaceutical and other applications. - FY2019RestatedAnnual report
「However, the Specialty Chemicals business posted lower revenue as pharmaceutical applications declined due to intensifying competition. Meanwhile, the Resin Materials business posted higher revenue as demand for urethane raw materials and materials for tire applications increased.」
The pattern of a decline in pharmaceutical applications due to intensifying competition being offset by increased demand for resin-related products was also evident for the full fiscal year. - FY2019-Q3ReframedAnnual report
「Although pharmaceutical applications declined due to intensifying competition, the Specialty Chemicals business remained in line with the same period of the previous year as demand for resin-related and other applications increased.」
Increased demand for resin-related and other applications offset the decline caused by intensifying competition in pharmaceutical applications, returning performance to the pattern of remaining in line with the same period of the previous year. - FY2019-Q2ReframedAnnual report
「Meanwhile, the Specialty Chemicals business posted lower revenue due to intensifying competition in pharmaceutical applications.」
Although the result of lower revenue in the Specialty Chemicals business continued, the stated factor changed from declining demand in pharmaceutical applications in the previous quarter to intensifying competition in pharmaceutical applications this time. - FY2019-Q1WorsenedAnnual report
「Meanwhile, the Specialty Chemicals business posted lower revenue as demand for pharmaceutical applications declined.」
Performance deteriorated from a period in which increased demand for resin-related applications resulted in higher revenue to lower revenue due to declining demand for pharmaceutical applications. - FY2018-Q3ReframedAnnual report
「The Specialty Chemicals business posted higher revenue as demand for resin-related and other applications increased.」
The explanation has changed from the previous description that resin-related and other applications offset the decline in pharmaceutical applications, leaving performance in line with the same period of the previous year, to a direct indication of increased demand and higher revenue in resin-related and other applications. - FY2018-Q2RestatedAnnual report
「Although pharmaceutical applications declined, the Specialty Chemicals business remained in line with the same period of the previous year as demand for resin-related and other applications increased.」
Increased demand for resin-related and other applications offset the decline in pharmaceutical applications, allowing the Specialty Chemicals business to remain in line with the same period of the previous year. - FY2018-Q1First statedAnnual report
「The Specialty Chemicals business remained in line with the same period of the previous year in both resin-related and pharmaceutical applications.」
This is the first time it has been stated that both resin-related and pharmaceutical applications in the Specialty Chemicals business remained in line with the same period of the previous year.